Diabetes vaccine developer Diamyd Medical is running a Phase II test to see if its candidate, Diamyd, can prevent or delay the onset of Type 1 diabetes in children at very high risk of presenting with the disease.
With its candidate diabetes vaccine in Phase II combo studies, Diamyd Medical is seeing some new investment--including a bumped-up agreement with longtime partner Protein Sciences.
Swedish company Diamyd Medical has sold off its U.S. subsidiary, Diamyd, and its nerve-delivery system, designed to deliver drugs to treat pain directly to the nervous system. The buyer is Periphagen Holdings, a company created and owned by the Diamyd management.
University of Michigan researchers are reporting success in easing pain in cancer sufferers using gene therapy delivered by a modified herpes simplex virus (HSV). David Fink, chair of the Department